Dr. Bryan Hartley

Well, again, this is the advantage of thinking of assume invention and think backwards. We originally thought our product was going to be a device. And when we looked at existing codes for placement of a device into the bladder or installation of a product into the bladder, the codes existed, but they reimbursed very low.

Well, again, this is the advantage of thinking of assume invention and think backwards. We originally thought our product was going to be a device. And when we looked at existing codes for placement of a device into the bladder or installation of a product into the bladder, the codes existed, but they reimbursed very low.

It would not be worth it to bring a product to market if that's all you could charge. And that was an inescapable, it felt like an inescapable problem. And so one of the first pivots we did was we decided we were going to be a drug company. Because if you go to a hospital with a device, you go through this thing called a value analysis committee. And they look at your product.

It would not be worth it to bring a product to market if that's all you could charge. And that was an inescapable, it felt like an inescapable problem. And so one of the first pivots we did was we decided we were going to be a drug company. Because if you go to a hospital with a device, you go through this thing called a value analysis committee. And they look at your product.

It would not be worth it to bring a product to market if that's all you could charge. And that was an inescapable, it felt like an inescapable problem. And so one of the first pivots we did was we decided we were going to be a drug company. Because if you go to a hospital with a device, you go through this thing called a value analysis committee. And they look at your product.

Let's say you're an orthopedic company. You have some new plate or new screw. Well, they look at that and then they say, well, this looks like something from Home Depot. I can buy it at Home Depot for five bucks and you're trying to charge me 400. We'll pay you 50, you know, and then and then the negotiation starts.

Let's say you're an orthopedic company. You have some new plate or new screw. Well, they look at that and then they say, well, this looks like something from Home Depot. I can buy it at Home Depot for five bucks and you're trying to charge me 400. We'll pay you 50, you know, and then and then the negotiation starts.

Let's say you're an orthopedic company. You have some new plate or new screw. Well, they look at that and then they say, well, this looks like something from Home Depot. I can buy it at Home Depot for five bucks and you're trying to charge me 400. We'll pay you 50, you know, and then and then the negotiation starts.

Whereas if you go to a value analysis committee with a drug, that's a witch's brew. Like, who knows how to make a drug? So you have a lot more pricing power and you don't have this thing that's anchoring it to it should be worth nothing. You can actually anchor it to the value you're delivering for the patients. So there were advantages to being a drug.

Whereas if you go to a value analysis committee with a drug, that's a witch's brew. Like, who knows how to make a drug? So you have a lot more pricing power and you don't have this thing that's anchoring it to it should be worth nothing. You can actually anchor it to the value you're delivering for the patients. So there were advantages to being a drug.

Whereas if you go to a value analysis committee with a drug, that's a witch's brew. Like, who knows how to make a drug? So you have a lot more pricing power and you don't have this thing that's anchoring it to it should be worth nothing. You can actually anchor it to the value you're delivering for the patients. So there were advantages to being a drug.

The disadvantage was we had no idea what we were doing. We didn't learn how to develop drugs. We didn't learn how to do a drug company. I didn't know anything about that regulatory path. I ended up going on Amazon and trying to search for how do you run a drug company and buying those books and reading them, completely unhelpful.

The disadvantage was we had no idea what we were doing. We didn't learn how to develop drugs. We didn't learn how to do a drug company. I didn't know anything about that regulatory path. I ended up going on Amazon and trying to search for how do you run a drug company and buying those books and reading them, completely unhelpful.

The disadvantage was we had no idea what we were doing. We didn't learn how to develop drugs. We didn't learn how to do a drug company. I didn't know anything about that regulatory path. I ended up going on Amazon and trying to search for how do you run a drug company and buying those books and reading them, completely unhelpful.

And it was a useful experience because what you learn along the way is that you actually don't need to know. You just need to know what to do next. And so long as you keep doing the thing you need to do next, that goes slow enough that the future kind of fills in. You get the right people around you and you can figure it out. That's awesome.

And it was a useful experience because what you learn along the way is that you actually don't need to know. You just need to know what to do next. And so long as you keep doing the thing you need to do next, that goes slow enough that the future kind of fills in. You get the right people around you and you can figure it out. That's awesome.

And it was a useful experience because what you learn along the way is that you actually don't need to know. You just need to know what to do next. And so long as you keep doing the thing you need to do next, that goes slow enough that the future kind of fills in. You get the right people around you and you can figure it out. That's awesome.

Today, we have completed two clinical trials in healthy patients with a placebo version of our product, proving that we can deliver it and that it's retained and that it's safe. And in parallel to that, we've demonstrated in the lab in a bladder model that we can release the drug over the course of several weeks out to several months at a level that would be meaningful for bladder disease.

Today, we have completed two clinical trials in healthy patients with a placebo version of our product, proving that we can deliver it and that it's retained and that it's safe. And in parallel to that, we've demonstrated in the lab in a bladder model that we can release the drug over the course of several weeks out to several months at a level that would be meaningful for bladder disease.

Today, we have completed two clinical trials in healthy patients with a placebo version of our product, proving that we can deliver it and that it's retained and that it's safe. And in parallel to that, we've demonstrated in the lab in a bladder model that we can release the drug over the course of several weeks out to several months at a level that would be meaningful for bladder disease.